Mesenchymal stem cells in drug/gene delivery: implications for cell therapy

被引:56
作者
Greco, Steven J. [1 ]
Rameshwar, Pranela [1 ]
机构
[1] Univ Med & Dent New Jersey, New Jersey Med Sch, MSB,Room E 579,185 South Orange Ave, Newark, NJ 07103 USA
关键词
D O I
10.4155/TDE.12.69
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Stem cells have been therapeutically utilized in replacement of hematopoetic cells for decades. This is in contrast to the recent emergence of adult stem cells as, perhaps, safe and beneficial therapeutics for multiple diseases and disorders. In particular, mesenchymal stem cells (MSCs) are currently used in multiple human clinical trials. Although MSCs are ubiquitous, bone marrow, umbilical cord and adipose tissue are the source-s where MSCs are isolated for research and clinical application. MSCs were thought to be mesodermal due to the initial reports showing their differentiation into specialized mesodermal cells such as chondrocytes. However, it now appears that MSCs might be neuroectodermal in origin. Thus far, there is no evidence of in vivo transformation of MSCs. However, it is too early to prove or disprove that MSCs can be transformed in vivo in clinical trials. MSCs display immunosuppressive properties when placed in a milieu of inflammatory mediators. This phenotype makes MSCs easily available for therapies as 'off-the-shelf' cells. Additionally, MSCs express chemotactic receptors, thereby allowing them to migrate to sites of tissue injury. This latter property has proven useful in the embodiment of MSCs as cellular vehicles to deliver targeted therapeutics to precise regions. The MSCs would typically harbor a prodrug or ectopically express a therapeutic gene to be delivered at a targeted site. This approach has been utilized in a number of different indications requiring precise therapeutic delivery, specifically cancer, cardiovascular disorders and neurodegenerative diseases. Combined with their immune-privileged status, safe clinical profile and low tumorigenicity, MSCs offer vast potential to benefit patients with serious diseases, for which limited treatment options exist.
引用
收藏
页码:997 / 1004
页数:8
相关论文
共 63 条
[1]   Single intra-arterial injection of mesenchymal stromal cells for treatment of steroid-refractory acute graft-versus-host disease: a pilot study [J].
Arima, Nobuyoshi ;
Nakamura, Fumiaki ;
Fukunaga, Akiko ;
Hirata, Hirokazu ;
Machida, Hiroko ;
Kouno, Shigene ;
Ohgushi, Hajime .
CYTOTHERAPY, 2010, 12 (02) :265-268
[2]   Mesenchymal Stem Cells Modified with a Single-Chain Antibody against EGFRvIII Successfully Inhibit the Growth of Human Xenograft Malignant Glioma [J].
Balyasnikova, Irina V. ;
Ferguson, Sherise D. ;
Sengupta, Sadhak ;
Han, Yu ;
Lesniak, Maciej S. .
PLOS ONE, 2010, 5 (03)
[3]   A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1) [J].
Bleul, CC ;
Fuhlbrigge, RC ;
Casasnovas, JM ;
Aiuti, A ;
Springer, TA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (03) :1101-1109
[4]   Adipose Tissue-derived Mesenchymal Stem Cells Expressing Prodrug-converting Enzyme Inhibit Human Prostate Tumor Growth [J].
Cavarretta, Ilaria T. ;
Altanerova, Veronika ;
Matuskova, Miroslava ;
Kucerova, Lucia ;
Culig, Zoran ;
Altaner, Cestmir .
MOLECULAR THERAPY, 2010, 18 (01) :223-231
[5]   Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-γ [J].
Chan, Jennifer L. ;
Tang, Katherine C. ;
Patel, Anoop P. ;
Bonilla, Larissa M. ;
Pierobon, Nicola ;
Ponzio, Nicholas M. ;
Rameshwar, Pranela .
BLOOD, 2006, 107 (12) :4817-4824
[6]   The neuroprotective effect of erythropoietin-transduced human mesenchymal stromal cells in an animal model of ischemic stroke [J].
Cho, Goang-Won ;
Koh, Seong-Ho ;
Kim, Mi-Hwa ;
Yoo, A. Rum ;
Noh, Min Young ;
Oh, Sechul ;
Kim, Seung Hyun .
BRAIN RESEARCH, 2010, 1353 :1-13
[7]   Human adipose tissue-derived mesenchymal stem cells: Characteristics and therapeutic potential as cellular vehicles for prodrug gene therapy against brainstem gliomas [J].
Choi, Seung Ah ;
Lee, Ji Yeoun ;
Wang, Kyu-Chang ;
Phi, Ji Hoon ;
Song, Sang Hoon ;
Song, Junghan ;
Kim, Seung-Ki .
EUROPEAN JOURNAL OF CANCER, 2012, 48 (01) :129-137
[8]   Therapeutic efficacy and safety of TRAIL-producing human adipose tissue-derived mesenchymal stem cells against experimental brainstem glioma [J].
Choi, Seung Ah ;
Hwang, Sung-Kyun ;
Wang, Kyu-Chang ;
Cho, Byung-Kyu ;
Phi, Ji Hoon ;
Lee, Ji Yeoun ;
Jung, Hee Won ;
Lee, Do-Hun ;
Kim, Seung-Ki .
NEURO-ONCOLOGY, 2011, 13 (01) :61-69
[9]   The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments [J].
Connick, Peter ;
Kolappan, Madhan ;
Patani, Rickie ;
Scott, Michael A. ;
Crawley, Charles ;
He, Xiao-Ling ;
Richardson, Karen ;
Barber, Kelly ;
Webber, Daniel J. ;
Wheeler-Kingshott, Claudia A. M. ;
Tozer, Daniel J. ;
Samson, Rebecca S. ;
Thomas, David L. ;
Du, Ming-Qing ;
Luan, Shi L. ;
Michell, Andrew W. ;
Altmann, Daniel R. ;
Thompson, Alan J. ;
Miller, David H. ;
Compston, Alastair ;
Chandran, Siddharthan .
TRIALS, 2011, 12
[10]   Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients [J].
Davatchi, Fereydoun ;
Abdollahi, Bahar Sadeghi ;
Mohyeddin, Mandana ;
Shahram, Farhad ;
Nikbin, Behrooz .
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2011, 14 (02) :211-215